Achieve Life Sciences has rebranded to align its name and stock ticker with its focus on helping people quit smoking and vaping.
Following the rebrand, the organization will do business as AchieveRx, The Quit Company. AchieveRx will change its stock ticker from ACHV to QUIT. The company is rebranding as it prepares to refile for FDA approval of cytisinicline to treat nicotine dependence. Having received a complete response letter in June, the biotech aims to win approval on the second attempt next year.
The new name and stock ticker are part of a broader refocusing of the company in preparation for the commercialization of cytisinicline. In recent months, AchieveRx has hired Mark Zappia and Jim Willis as senior vice president of commercial and vice president of sales and sales enablement, respectively. The company also appointed Kaitlyn Tuson as senior vice president of marketing and communications.
Zappia, Willis and Tuson are working under Andrew Goldberg, M.D., who joined the company as CEO in April. AchieveRx raised $180 million—and secured up to $174 million linked to FDA approval—when it hired Goldberg.
The FDA delayed the company’s transition into a commercial business by rejecting the cytisinicline filing on manufacturing grounds. AchieveRx is transferring finished product manufacturing to U.S.-based Adare Pharma Solutions and has hired production and quality leaders, putting it on track to refile for FDA approval this year and launch cytisinicline in the U.S. in the first half of 2027.
AchieveRx, which plans to commercialize cytisinicline independently with its own field force, stepped up launch planning in July 2025. Back then, the biotech partnered with Omnicom to use generative artificial intelligence, predictive analytics and social listening for targeting and personalization. The technologies will support a strategy shaped around the unique characteristics of the nicotine-dependence market.
“Launch efficiency in this category is not about saturating awareness. Patients already raised their hands. It is about giving prescribers a reason to treat, equipping them with the right therapy and removing that access friction,” Goldberg said on an earnings call in May.